Contract pharmaceutical manufacturing, research and packaging

710 views

Published on

Published in: Business, Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
710
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
23
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Contract pharmaceutical manufacturing, research and packaging

  1. 1. Contract Pharmaceutical Manufacturing, Research and Packaging: Global MarketsPublished:September 2011No.Of Pages:372Price:US $ 4850Report Summary* The global pharmaceutical contract manufacturing and contract researchorganizations revenue reached at $196.5 billion in 2010, it will further grow to$217.9 billion in 2011 and is projected to reach at $360.6 billion by 2016,increasing at a compound annual growth rate (CAGR) of 10.6%.* Contract manufacturing of OTC and nutritional products worldwide reached at$114.8 billion in 2010, it will further grow to $127.9 billion in 2011 and is projectedto reach at $214.5 billion by 2016, increasing at a compound annual growth rate(CAGR) of 10.9%.* Contract manufacturing of bulk and dosage form drugs worldwide reached at$48.6 billion in 2010, it will further grow to $53.4 billion in 2011 and is projected toreach at $86.3 billion by 2016, increasing at a compound annual growth rate(CAGR) of 10.1%.STUDY OBJECTIVEThe objective of BCC Research in conducting this study is to provide an overview ofthe current situation and future capabilities of the global pharmaceutical contractmanufacturing, research, and packaging markets. The study provides a global aswell as a regionally specific market overview. The report emphasizes the currentand future outlook of the pharmaceutical contract manufacturing market, with acomprehensive analysis of the overall pharmaceutical and biotechnologyoutsourcing industry.The current report discusses and outlines the current capabilities as well as theneeds of the pharmaceutical contract manufacturing, research, and packagingmarkets. In addition, it discusses company and market strategies to furtherenhance the market. The report includes the different types of contractmanufacturing and, more specifically, the services offered by global contractmanufacturers, researchers, and packagers. The report also discusses the methodsbest used to identify an effective contract manufacturer as well as the advantagesof contract manufacturing and outsourcing. The report highlights the need forproject management, provides market forecasts for different aspects of contractmanufacturing specific to each region, and examines the role of market leaders inthe industry. Regulatory requirements and new developments in the market arealso discussed in the report.
  2. 2. The report encompasses the revenues gained from contract manufacturing in eachspecific market and in each specific region. Sales analysis was performed onspecific categories of drugs and dosage forms including API/bulk drugs and solid,liquid, and semisolid dosage forms. Sales analyses were also performed onrevenues gained from contract packaging and contract research. The sales figuresdiscussed are for the examined period of 2009 to 2011. Sales figures were alsoforecast for the following 5-year period from 2011 through 2016.Over-the-counter (OTC) drugs, nutritional drugs, and drug delivery products arediscussed in a separate section of this report.Browse All Pharmaceuticals Market Research ReportsREASONS FOR DOING THIS STUDYThe majority of pharmaceutical companies are now using contract manufacturing,research, and packaging services. To save costs and product development timewhile simultaneously being effective, efficient, and productive, pharmaceuticalcompanies are relying on contract manufacturers to fulfill many basic as well asspecialized competencies. This study discusses the different types of contractingcompanies, their roles, and the share of the market they claim. New developmentsand new technologies warrant the issuing of this report, which is an importantresource for anyone analyzing the discussed markets.Trends in outsourcing and new emerging markets for outsourcing are providing anew look to the market and greater options to pharmaceutical companies. Theindustry is seeing an increase in outsourcing as contract manufacturers,researchers, and packagers provide cheaper options as well as region-specificsuppliers. The new state-of-the-art packaging facilities as well as expensiveresearch facilities and capabilities of research organizations are enhancing theoverall growth of the contract manufacturing industry. Contract manufacturers areproviding pharmaceutical companies with expertise in all forms that the companiesdo not have available in-house.INTENDED AUDIENCEThis study examines the areas of market growth in pharmaceuticals contractmanufacturing, research, and packaging from the point of view of manufacturersand users. Strategic decision makers at biochemical and biotechnology companies,physicians, pharmaceuticals and biopharmaceuticals companies, and relatedresearch companies will find value in this study.SCOPE OF THE STUDYThe scope of this study encompasses the contract manufacturing, research, andpackaging markets. BCC analyzes each market and its applications for contract
  3. 3. manufacturing by its need for outsourcing, regulatory environment, technologyinvolved, market projections, and market share. Technological issues include thelatest trends and developments.METHODOLOGYBoth primary and secondary research methodologies were used in preparing thisstudy. BCC conducted a comprehensive literature search, which included technicalnewsletters and journals, and many other sources. Data were collected throughinterviews and correspondence with various analytical, chemical, pharmaceutical,and contracting experts. Market sizing estimates and projections were based onestimates such as the current number of end users, potential end users, mergersand acquisitions, and market trends.INFORMATION SOURCESMany companies within the industry were surveyed to obtain data for this study.Included were manufacturers and end users of pharmaceuticals through contractmanufacturing and research. Data were gathered from various industry sources.BCC spoke with officials and physicians within the industry, and consultednewsletters, company literature, product literature, and a host of technical articles,journals, indexes, and abstracts. Exhaustive investigations of databases by keyterminology were completed. In addition, data were compiled from currentfinancial, trade, and government sources.Table Of ContentsCHAPTER ONE: INTRODUCTIONSTUDY OBJECTIVEREASONS FOR DOING THIS STUDYINTENDED AUDIENCESCOPE OF THE STUDYMETHODOLOGYINFORMATION SOURCESABOUT THE AUTHORRELATED BCC RESEARCH REPORTSBCC ONLINE SERVICESDISCLAIMERCHAPTER TWO: SUMMARYSUMMARYSUMMARY TABLE GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING ANDCONTRACT RESEARCH ORGANIZATIONS REVENUE, THROUGH 2016 ($ BILLIONS)
  4. 4. SUMMARY FIGURE GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING ANDCONTRACT RESEARCH ORGANIZATIONS REVENUE, 2009-2016 ($ BILLIONS)CHAPTER THREE: OVERVIEWDEFINITIONSHISTORY OF OUTSOURCINGTABLE 1 KEY DEVELOPMENTS IN THE HISTORY OF OUTSOURCINGCHAPTER FOUR: OVERVIEW OF CONTRACT MANUFACTURINGTYPES OF CONTRACT MANUFACTURERSCONTRACT MANUFACTURING TRAITSREQUIREMENTABILITY TO BE FLEXIBLECAPABILITIES WITHOUT COSTADVANTAGES AND DISADVANTAGES OF CONTRACT MANUFACTURINGTABLE 2 KEY ADVANTAGES OF CONTRACT MANUFACTURINGTABLE 3 KEY DISADVANTAGES OF CONTRACT MANUFACTURINGSELECTING A CONTRACT MANUFACTURERTABLE 4 KEY FACTORS IN SELECTING A CONTRACT MANUFACTURERADDITIONAL FACTS ABOUT CONTRACT MANUFACTURINGLOCATION AND PROXIMITYAFTER-SALES SUPPORTCHAPTER FIVE: OVERVIEW OF CONTRACT RESEARCHOVERVIEW OF CONTRACT RESEARCHSERVICES OFFERED BY CONTRACT RESEARCH ORGANIZATIONSTABLE 5 SERVICES OF CONTRACT RESEARCH ORGANIZATIONSSELECTING A CONTRACT RESEARCH ORGANIZATIONTABLE 6 KEY CHARACTERISITCS IN SELECTING A CONTRACT RESEARCHORGANIZATIONRESEARCH PROVIDED BY CONTRACT RESEARCH ORGNIZATIONSTABLE 7 TYPES OF RESEARCH PROVIDED BY CONTRACT RESEARCHORGANIZATIONSCHAPTER SIX: OVERVIEW OF CONTRACT PACKAGINGNEEDING A CONTRACT PACKAGERTABLE 8 REASONS BEHIND NEEDING A CONTRACT PACKAGERSELECTING A CONTRACT PACKAGERTABLE 9 KEY CHARACTERISTICS IN SELECTING A CONTRACT PACKAGERHIRING A CONTRACT PACKAGERTABLE 10 KEY STEPS IN HIRING A CONTRACT PACKAGERTYPES OF PACKAGINGCHAPTER SEVEN: PROJECT MANAGEMENTSPECIFICATIONS OF PROJECT MANAGEMENTTABLE 11 STEPS OF PROJECT MANAGEMENTPROCESSES OF PROJECT MANAGEMENT
  5. 5. TABLE 12 PROCESSES OF PROJECT MANAGEMENTFACTORS INVOLVEDROLE OF THE PROJECT MANAGERTABLE 13 KEY RESPONSIBILITIES OF PROJECT MANAGERSTECHNOLOGY TRANSFERTABLE 14 TECHNOLOGY TRANSFER STEPSCHAPTER EIGHT: REGULATORY ASPECTSREGULATORY ASPECTSTABLE 15 REGULATED FACTORS OF CMO’S AND CRO’STABLE 16 TITLE 21 CFR RULES ASSOCIATED WITH CONTRACT MANUFACTURINGWARNING LETTERSTABLE 17 WARNING LETTERS ISSUED TO CONTRACT MANUFACTURERS, 2010TABLE 18 WARNING LETTERS ISSUED TO CONTRACT MANUFACTURERS, 2009REGULATORY APPROVALSTABLE 9 REGULATORY APPROVALS OF CONTRACT MANUFACTURERS ANDFACILITIES, JANUARY THROUGH MARCH, 2011TABLE 20 REGULATORY APPROVALS OF CONTRACT MANUFACTURERS ANDFACILITIES, 2010TABLE 21 REGULATORY APPROVALS OF CONTRACT MANUFACTURERS ANDFACILITIES, 2009CHAPTER NINE: INDUSTRY STRUCTURE FOR NORTH AMERICAMARKET SHARE OF INDUSTRY LEADERSCONTRACT MANUFACTURERS OF BULK DRUGS AND API’STABLE 22 MARKET SHARE OF CONTRACT MANUFACTURING COMPANIESPROVIDING BULK DRUGS/API’S, IN NORTH AMERICA, 2010 (%)FIGURE 1 MARKET SHARE OF CONTRACT MANUFACTURING COMPANIESPROVIDING BULK DRUGS/API’S, IN NORTH AMERICA, 2010 (%)CONTRACT MANUFACTURERS OF SOLID-DOSAGE FORMSTABLE 23 MARKET SHARE OF CONTRACT MANUFACTURING COMPANIESPROVIDING SOLID DOSAGE FORMS, IN NORTH AMERICA, 2010 (%)FIGURE 2 MARKET SHARE OF CONTRACT MANUFACTURING COMPANIESPROVIDING SOLID DOSAGE FORMS, IN NORTH AMERICA, 2010 (%)CONTRACT MANUFACTURERS OF LIQUID DOSAGE FORMSNONSTERILETABLE 24 MARKET SHARE OF CONTRACT MANUFACTURING COMPANIESPROVIDING NONSTERILE LIQUID DOSAGE FORMS, IN NORTH AMERICA, 2010 (%)FIGURE 3 MARKET SHARE OF CONTRACT MANUFACTURING COMPANIESPROVIDING NONSTERILE LIQUID DOSAGE FORMS, IN NORTH AMERICA, 2010 (%)STERILETABLE 25 MARKET SHARE OF CONTRACT MANUFACTURING COMPANIESPROVIDING STERILE LIQUID DOSAGE FORMS, IN NORTH AMERICA, 2010 (%)FIGURE 4 MARKET SHARE OF CONTRACT MANUFACTURING COMPANIESPROVIDING STERILE LIQUID DOSAGE FORMS, IN NORTH AMERICA, 2010 (%)CONTRACT MANUFACTURERS OF SEMISOLID DOSAGE FORMSTABLE 26 MARKET SHARE OF CONTRACT MANUFACTURING COMPANIES
  6. 6. PROVIDING SEMISOLID DOSAGE FORMS, IN NORTH AMERICA, 2010 (%)FIGURE 5 MARKET SHARE OF CONTRACT MANUFACTURING COMPANIESPROVIDING SEMISOLID DOSAGE FORMS, IN NORTH AMERICA, 2010 (%)CONTRACT RESEARCH COMPANIESTABLE 27 MARKET SHARE OF CONTRACT RESEARCH COMPANIES, IN NORTHAMERICA, 2010 (%)FIGURE 6 MARKET SHARE OF CONTRACT RESEARCH COMPANIES, IN NORTHAMERICA, 2010 (%)CONTRACT PACKAGING COMPANIESTABLE 28 MARKET SHARE OF CONTRACT PACKAGING COMPANIES, IN NORTHAMERICA 2010 (%)FIGURE 7 MARKET SHARE OF CONTRACT PACKAGING COMPANIES, IN NORTHAMERICA, 2010 (%)CHAPTER TEN: INDUSTRY STRUCTURE FOR EUROPEMARKET SHARE OF INDUSTRY LEADERSCONTRACT MANUFACTURERS OF BULK DRUGS AND API’STABLE 29 MARKET SHARE OF CONTRACT MANUFACTURING COMPANIESPROVIDING BULK DRUGS/API’S, IN EUROPE, 2010 (%)FIGURE 8 MARKET SHARE OF CONTRACT MANUFACTURING COMPANIESPROVIDING BULK DRUGS/API’S, IN EUROPE, 2010 (%)CONTRACT MANUFACTURERS OF SOLID DOSAGE FORMSTABLE 30 MARKET SHARE OF CONTRACT MANUFACTURING COMPANIESPROVIDING SOLID DOSAGE FORMS, IN EUROPE, 2010 (%)FIGURE 9 MARKET SHARE OF CONTRACT MANUFACTURING COMPANIESPROVIDING SOLID DOSAGE FORMS, IN EUROPE, 2010 (%)CONTRACT MANUFACTURERS OF LIQUID DOSAGE FORMSNONSTERILETABLE 31 MARKET SHARE OF CONTRACT MANUFACTURING COMPANIESPROVIDING NONSTERILE LIQUID DOSAGE FORMS, IN EUROPE, 2010 (%)FIGURE 10 MARKET SHARE OF CONTRACT MANUFACTURING COMPANIESPROVIDING NONSTERILE LIQUID DOSAGE FORMS, IN EUROPE, 2010 (%)STERILETABLE 32 MARKET SHARE OF CONTRACT MANUFACTURING COMPANIESPROVIDING STERILE LIQUID DOSAGE FORMS, IN EUROPE, 2010 (%)FIGURE 11 MARKET SHARE OF CONTRACT MANUFACTURING COMPANIESPROVIDING STERILE LIQUID DOSAGE FORMS, IN EUROPE, 2010 (%)CONTRACT MANUFACTURING OF SEMISOLID DOSAGE FORMSTABLE 33 MARKET SHARE OF CONTRACT MANUFACTURING COMPANIESPROVIDING SEMISOLID DOSAGE FORMS, IN EUROPE, 2010 (%)FIGURE 12 MARKET SHARE OF CONTRACT MANUFACTURING COMPANIESPROVIDING SEMISOLID DOSAGE FORMS, IN EUROPE, 2010 (%)CONTRACT RESEARCH COMPANIESTABLE 34 MARKET SHARE OF CONTRACT RESEARCH COMPANIES, IN EUROPE,2010 (%)FIGURE 13 MARKET SHARE OF CONTRACT RESEARCH COMPANIES, IN EUROPE,2010 (%)
  7. 7. TABLE 35 MARKET SHARE OF CONTRACT PACKAGING COMPANIES, IN EUROPE,2010 (%)FIGURE 14 MARKET SHARE OF CONTRACT PACKAGING COMPANIES, IN EUROPE,2010 (%)CHAPTER ELEVEN: INDUSTRY STRUCTURE FOR EMERGING MARKETSMARKET SHARE OF INDUSTRY LEADERSCONTRACT MANUFACTURERS OF BULK DRUGS AND API’STABLE 36 MARKET SHARE OF CONTRACT MANUFACTURING COMPANIESPROVIDING BULK DRUGS/API’S, IN REST OF WORLD, 2010 (%)FIGURE 15 MARKET SHARE OF CONTRACT MANUFACTURING COMPANIESPROVIDING BULK DRUGS/API’S, IN REST OF WORLD, 2010 (%)CONTRACT MANUFACTURERS OF SOLID DOSAGE FORMSTABLE 37 MARKET SHARE OF CONTRACT MANUFACTURING COMPANIESPROVIDING SOLID DOSAGE FORMS, 2010 (%)FIGURE 16 MARKET SHARE OF CONTRACT MANUFACTURING COMPANIESPROVIDING SOLID DOSAGE FORMS, IN REST OF WORLD, 2010 (%)CONTRACT MANUFACTURERS OF LIQUID DOSAGE FORMSNONSTERILETABLE 38 MARKET SHARE OF CONTRACT MANUFACTURING COMPANIESPROVIDING NONSTERILE LIQUID DOSAGE FORMS, IN REST OF WORLD, 2010 (%)FIGURE 17 MARKET SHARE OF CONTRACT MANUFACTURING COMPANIESPROVIDING NONSTERILE LIQUID DOSAGE FORMS, IN REST OF WORLD, 2010 (%)STERILETABLE 39 MARKET SHARE OF CONTRACT MANUFACTURING COMPANIESPROVIDING STERILE LIQUID DOSAGE FORMS, IN REST OF WORLD, 2010 (%)FIGURE 18 MARKET SHARE OF CONTRACT MANUFACTURING COMPANIESPROVIDING STERILE LIQUID DOSAGE FORMS, IN REST OF WORLD, 2010 (%)CONTRACT MANUFACTURING OF SEMISOLID DOSAGE FORMSTABLE 40 MARKET SHARE OF CONTRACT MANUFACTURING COMPANIESPROVIDING SEMISOLID DOSAGE FORMS, IN REST OF WORLD, 2010 (%)FIGURE 19 MARKET SHARE OF CONTRACT MANUFACTURING COMPANIESPROVIDING SEMISOLID DOSAGE FORMS, IN REST OF WORLD, 2010 (%)CONTRACT RESEARCH COMPANIESTABLE 41 MARKET SHARES OF CONTRACT RESEARCH COMPANIES, IN REST OFWORLD, 2010 (%)FIGURE 20 MARKET SHARES OF CONTRACT RESEARCH COMPANIES, IN REST OFWORLD, 2010 (%)CONTRACT PACKAGING COMPANIESTABLE 42 MARKET SHARE OF CONTRACT PACKAGING COMPANIES, IN REST OFWORLD, 2010 (%)FIGURE 21 MARKET SHARE OF CONTRACT PACKAGING COMPANIES, IN REST OFWORLD, 2010 (%)TYPES OF CONTRACT MANUFACTURING AND RESEARCH FIRMSTABLE 43 SERVICES PROVIDED BY CONTRACT MANUFACTURING AND RESEARCHFIRMS TABLE 44 SERVICES PROVIDED BY CONTRACT PACKAGING FIRMS BYPACKAGING TYPE
  8. 8. CHAPTER TWELVE: TECHNOLOGY TRANSFERREASONS FOR TECHNOLOGY TRANSFERCHALLENGING PROBLEMS DURING TECHNOLOGY TRANSFERTECHNOLOGY TRANSFERSTEPS FOR SUCCESSFUL TECHNOLOGY TRANSFERTYPES OF CONTRACTUAL AGREEMENTS USED IN TECHNOLOGY TRANSFERCONFIDENTIAL DISCLOSURE AGREEMENT (CDA)MATERIAL TRANSFER AGREEMENT (MTA)ASSIGNMENT DEEDLICENSE AGREEMENTCO-DEVELOPMENT AND CO-MARKETING AGREEMENTSCHARACTERISTICS OF A SUCCESSFUL PROJECTCHAPTER THIRTEEN: NEW DEVELOPMENTSLONZAABBOTTHOSPIRACOVIDIENOTHERCHAPTER FOURTEEN: MARKET ANALYSIS FOR NORTH AMERICACONTRACT MANUFACTURINGCONTRACT MANUFACTURE OF BULK DRUGS/API’SMarket OverviewMarket RevenueTABLE 45 BULK DRUG/API CONTRACT MANUFACTURING, FOR NORTH AMERICA,THROUGH 2016 ($ BILLIONS)FIGURE 22 BULK DRUG/API CONTRACT MANUFACTURING, FOR NORTH AMERICA,2009-2016 ($ BILLIONS)CONTRACT MANUFACTURE OF DOSAGE FORMULATIONSSolid Dosage FormulationsMarket OverviewMarket RevenueTABLE 46 SOLID DOSAGE FORM CONTRACT MANUFACTURING, FOR NORTHAMERICA, THROUGH 2016 ($ BILLIONS)FIGURE 23 SOLID DOSAGE FORM CONTRACT MANUFACTURING, FOR NORTHAMERICA, 2009-2016 ($ BILLIONS)Market by FormulationMarket RevenueTABLE 47 SOLID DOSAGE FORM CONTRACT MANUFACTURING REVENUE, BYFORMULATION, FOR NORTH AMERICA, THROUGH 2016 ($ BILLIONS)FIGURE 24 SOLID DOSAGE FORM CONTRACT MANUFACTURING REVENUE, BYFORMULATIONS, FOR NORTH AMERICA, 2009-2016 ($ BILLIONS)TABLE 48 SOLID DOSAGE FORM CONTRACT MANUFACTURING MARKET SHARES, BYFORMULATION, FOR NORTH AMERICA, 2010 (%)FIGURE 25 SOLID DOSAGE FORM CONTRACT MANUFACTURING MARKET SHARES,BY FORMULATIONS, FOR NORTH AMERICA, 2010 (%)
  9. 9. Liquid Dosage FormulationMarket OverviewMarket RevenueNonsterile FormulationsTABLE 49 LIQUID DOSAGE FORM (NONSTERILE) CONTRACT MANUFACTURING, FORNORTH AMERICA, THROUGH 2016 ($ MILLIONS)FIGURE 26 LIQUID DOSAGE FORM (NONSTERILE) CONTRACT MANUFACTURING,FOR NORTH AMERICA, 2009-2016 ($ MILLIONS)Sterile FormulationsTABLE 50 LIQUID DOSAGE FORM (STERILE) CONTRACT MANUFACTURING, FORNORTH AMERICA, THROUGH 2016 ($ MILLIONS)FIGURE 27 LIQUID DOSAGE FORM (STERILE) CONTRACT MANUFACTURING, FORNORTH AMERICA, THROUGH 2016 ($ MILLIONS)Market by FormulationNonsterile FormulationsTABLE 51 LIQUID DOSAGE FORM (NONSTERILE) CONTRACT MANUFACTURINGREVENUE, BY FORMULATION, FOR NORTH AMERICA, THROUGH 2016 ($ MILLIONS)FIGURE 28 LIQUID DOSAGE FORM (NON STERILE) CONTRACT MANUFACTURINGREVENUE, BY FORMULATION, FOR NORTH AMERICA, 2009-2016 ($ MILLIONS)TABLE 52 LIQUID DOSAGE FORM (NONSTERILE) CONTRACT MANUFACTURINGMARKET SHARES BY FORMULATION, FOR NORTH AMERICA, 2010 (%)FIGURE 29 LIQUID DOSAGE FORM (NONSTERILE) CONTRACT MANUFACTURINGMARKET SHARES, BY FORMULATION, FOR NORTH AMERICA, 2010 (%)Sterile FormulationsTABLE 53 LIQUID DOSAGE FORM (STERILE) CONTRACT MANUFACTURINGREVENUE, BY FORMULATION, FOR NORTH AMERICA, THROUGH 2016 ($ MILLIONS)FIGURE 30 LIQUID DOSAGE FORM (STERILE) CONTRACT MANUFACTURINGREVENUE, BY FORMULATION, FOR NORTH AMERICA, 2009-2016 ($ MILLIONS)TABLE 54 LIQUID DOSAGE FORM (STERILE) CONTRACT MANUFACTURING MARKETSHARE, BY FORMULATION, FOR NORTH AMERICA, 2010 (%)FIGURE 31 LIQUID DOSAGE FORM (STERILE) CONTRACT MANUFACTURINGMARKET SHARE, BY FORMULATION, FOR NORTH AMERICA, 2010 (%)CONTRACT MANUFACTURE OF SEMISOLID DOSAGE FORMULATIONSMarket OverviewMarket RevenueTABLE 55 SEMISOLID DOSAGE FORM CONTRACT MANUFACTURING, FOR NORTHAMERICA, THROUGH 2016 ($ MILLIONS)FIGURE 32 SEMISOLID DOSAGE FORM CONTRACT MANUFACTURING, FOR NORTHAMERICA, 2009-2016 ($ MILLIONS)TABLE 56 SEMISOLID DOSAGE FORM CONTRACT MANUFACTURING REVENUE, BYFORMULATION, FOR NORTH AMERICA, THROUGH 2016 ($ MILLIONS)FIGURE 33 SEMISOLID DOSAGE FORM CONTRACT MANUFACTURING REVENUE, BYFORMULATION, FOR NORTH AMERICA, 2009-2016 ($ MILLIONS)TABLE 57 SEMISOLID DOSAGE FORM CONTRACT MANUFACTURING MARKETSHARE, BY FORMULATION, FOR NORTH AMERICA, 2010 (%)FIGURE 34 SEMISOLID DOSAGE FORM CONTRACT MANUFACTURING MARKETSHARE, BY FORMULATION, FOR NORTH AMERICA, 2010 (%)
  10. 10. CONTRACT MANUFACTURE OF ADVANCED DRUG DELIVERY PRODUCTSMarket OverviewTABLE 58 CONTRACTING COMPANIES PROVIDING DRUGDELIVERYSYSTEMSMarket RevenueTABLE 59 ADVANCED DRUG DELIVERY SYSTEMS REVENUE BY CONTRACTMANUFACTURING, FOR NORTH AMERICA, THROUGH 2016 ($ BILLIONS)FIGURE 35 ADVANCED DRUG DELIVERY SYSTEMS REVENUE BY CONTRACTMANUFACTURING, FOR NORTH AMERICA, THROUGH 2016 ($ BILLIONS)Market by FormulationTABLE 60 ADVANCED DRUG DELIVERY SYSTEMS FOR NORTH AMERICA, BYCONTRACT MANUFACTURING REVENUE, BY FORMULATION, THROUGH 2016 ($MILLIONS)FIGURE 36 ADVANCED DRUG DELIVERY SYSTEMS FOR NORTH AMERICA, BYCONTRACT MANUFACTURING REVENUE, BY FORMULATIONS, 2009-2016 ($MILLIONS)Market ShareTABLE 61 ADVANCED DRUG DELIVERY SYSTEMS FOR NORTH AMERICA, BYCONTRACT MANUFACTURING MARKET SHARE, BY FORMULATION, 2010 (%)FIGURE 37 ADVANCED DRUG DELIVERY SYSTEMS FOR NORTH AMERICA, BYCONTRACT MANUFACTURING MARKET SHARE, BY FORMULATIONS, 2010 (%)CONTRACT MANUFACTURE OF OTC AND NUTRITIONAL PRODUCTSMarket OverviewMarket RevenueTABLE 62 OTC AND NUTRITIONAL PRODUCT REVENUE FOR NORTH AMERICA BYCONTRACT MANUFACTURING, THROUGH 2016 ($ BILLIONS)FIGURE 38 OTC AND NUTRITIONAL PRODUCT REVENUE FOR NORTH AMERICA BYCONTRACT MANUFACTURING, 2009-2016 ($ BILLIONS)Market by FormulationTABLE 63 OTC AND NUTRITIONAL PRODUCTS BY CONTRACT MANUFACTURINGREVENUE BY FORMULATION FOR NORTH AMERICA, THROUGH 2016 ($ BILLIONS)FIGURE 39 OTC AND NUTRITIONAL PRODUCTS BY CONTRACT MANUFACTURINGREVENUE, BY FORMULATION, FOR NORTH AMERICA, 2009-2016 ($ BILLIONS)Market SharesTABLE 64 OTC AND NUTRITIONAL PRODUCTS BY CONTRACT MANUFACTURINGMARKET SHARE, BY FORMULATION, FOR NORTH AMERICA, 2010 (%)FIGURE 40 OTC AND NUTRITIONAL PRODUCTS BY CONTRACT MANUFACTURINGMARKET SHARE, BY FORMULATIONS, FOR NORTH AMERICA, 2010 (%)CONTRACT RESEARCHMARKET OVERVIEWPartnershipsExpansions of FacilitiesMARKET REVENUETABLE 65 CONTRACT RESEARCH REVENUE FOR NORTH AMERICA, THROUGH 2016($ BILLIONS)FIGURE 41 CONTRACT RESEARCH REVENUE, FOR NORTH AMERICA, 2009-2016 ($BILLIONS)
  11. 11. Market by DisciplineTABLE 66 CONTRACT RESEARCH REVENUE BY DISCIPLINE, FOR NORTH AMERICA,THROUGH 2016 ($ BILLIONS)FIGURE 42 CONTRACT RESEARCH REVENUE BY DISCIPLINE, FOR NORTH AMERICA,2009-2016 ($ BILLIONS)Market Shares by DisciplineTABLE 67 CONTRACT RESEARCH MARKET SHARE, BY DISCIPLINE, FOR NORTHAMERICA, 2010 (%)FIGURE 43 CONTRACT RESEARCH MARKET SHARE, BY DISCIPLINE, FOR NORTHAMERICA, 2010 (%)CONTRACT PACKAGINGMARKET OVERVIEWMarket RevenueTABLE 68 CONTRACT PACKAGING REVENUE, FOR NORTH AMERICA, THROUGH2016 ($ BILLIONS)FIGURE 44 CONTRACT PACKAGING REVENUE, FOR NORTH AMERICA, 2009-2016 ($BILLIONS)Market by Package TypeTABLE 69 CONTRACT PACKAGING REVENUE BY TYPE, FOR NORTH AMERICA,THROUGH 2016 ($ MILLIONS)FIGURE 45 CONTRACT RESEARCH REVENUE BY DISCIPLINE, FOR NORTH AMERICA,2009-2016 ($ MILLIONS)Market Share by TypeTABLE 70 CONTRACT PACKAGING MARKET SHARE, BY TYPE, FOR NORTH AMERICA,2010 (%)FIGURE 46 CONTRACT PACKAGING MARKET SHARE, BY TYPE, FOR NORTHAMERICA, 2010 (%)CHAPTER FIFTEEN: MARKET ANALYSIS FOR EUROPECONTRACT MANUFACTURINGCONTRACT MANUFACTURE OF BULK DRUGS/API’SMarket OverviewMarket RevenueTABLE 71 BULK DRUG/API CONTRACT MANUFACTURING REVENUE, FOR EUROPE,THROUGH 2016 ($ BILLIONS)FIGURE 47 BULK DRUG/API CONTRACT MANUFACTURING REVENUE, FOR EUROPE,2009-2016 ($ BILLIONS)CONTRACT MANUFACTURE OF ORAL DOSAGE FORMULATIONSSolid Dosage FormulationsMarket OverviewMarket RevenueTABLE 72 SOLID DOSAGE FORM CONTRACT MANUFACTURING, FOR EUROPE,THROUGH 2016 ($ BILLIONS)FIGURE 48 SOLID DOSAGE FORM CONTRACT MANUFACTURING, FOR EUROPE,2009- 2016 ($ BILLIONS)Market by FormulationMarket Revenue
  12. 12. TABLE 73 SOLID DOSAGE FORM CONTRACT MANUFACTURING REVENUE, BYFORMULATION, FOR EUROPE, THROUGH 2016 ($ BILLIONS)FIGURE 49 SOLID DOSAGE FORM CONTRACT MANUFACTURING REVENUE, BYFORMULATIONS, FOR EUROPE, 2009-2016 ($ BILLIONS)TABLE 74 SOLID DOSAGE FORM CONTRACT MANUFACTURING MARKET SHARES, BYFORMULATION, FOR EUROPE, 2010 (%)FIGURE 50 SOLID DOSAGE FORM CONTRACT MANUFACTURING MARKET SHARES,BY FORMULATIONS, FOR EUROPE, 2010 (%)Liquid Dosage FormulationMarket OverviewMarket RevenueNonsterile FormulationsTABLE 75 LIQUID DOSAGE FORM (NONSTERILE) CONTRACT MANUFACTURING, FOREUROPE, THROUGH 2016 ($ MILLIONS)FIGURE 51 LIQUID DOSAGE FORM (NONSTERILE) CONTRACT MANUFACTURING,FOR EUROPE, 2009-2016 ($ MILLIONS)Sterile FormulationsTABLE 76 LIQUID DOSAGE FORM (STERILE) CONTRACT MANUFACTURING, FOREUROPE, THROUGH 2016 ($ MILLIONS)FIGURE 52 LIQUID DOSAGE FORM (STERILE) CONTRACT MANUFACTURING, FOREUROPE, 2009-2016 ($ MILLIONS)Market by FormulationNonsterile FormulationsTABLE 77 LIQUID DOSAGE FORM (NONSTERILE) CONTRACT MANUFACTURINGREVENUE, BY FORMULATION, FOR EUROPE, THROUGH 2016 ($ MILLIONS)FIGURE 53 LIQUID DOSAGE FORM (NONSTERILE) CONTRACT MANUFACTURINGREVENUE, BY FORMULATIONS, FOR EUROPE, 2009-2016 ($ MILLIONS)TABLE 78 LIQUID DOSAGE FORM (NONSTERILE) CONTRACT MANUFACTURINGMARKET SHARES, BY FORMULATION, FOR EUROPE, 2010 (%)FIGURE 54 LIQUID DOSAGE FORM (NONSTERILE) CONTRACT MANUFACTURINGMARKET SHARES, BY FORMULATIONS, FOR EUROPE, 2010 (%)Sterile FormulationsTABLE 79 LIQUID DOSAGE FORM (STERILE) CONTRACT MANUFACTURINGREVENUE, BY FORMULATION, FOR EUROPE, THROUGH 2016 ($ MILLIONS)FIGURE 55 LIQUID DOSAGE FORM (STERILE) CONTRACT MANUFACTURINGREVENUE, BY FORMULATION, FOR EUROPE, 2009-2016 ($ MILLIONS)TABLE 80 LIQUID DOSAGE FORM (STERILE) CONTRACT MANUFACTURING MARKETSHARE, BY FORMULATION, FOR EUROPE, 2010 (%)FIGURE 56 LIQUID DOSAGE FORM (STERILE) CONTRACT MANUFACTURINGMARKET SHARE, BY FORMULATIONS, FOR EUROPE, 2010 (%)CONTRACT MANUFACTURE OF SEMISOLID DOSAGE FORMULATIONSMarket OverviewMarket RevenueTABLE 81 SEMISOLID DOSAGE FORM CONTRACT MANUFACTURING, FOR EUROPE,THROUGH 2016 ($ MILLIONS)FIGURE 57 SEMISOLID DOSAGE FORM CONTRACT MANUFACTURING, FOR EUROPE,2009-2016 ($ MILLIONS)
  13. 13. TABLE 82 SEMISOLID DOSAGE FORM CONTRACT MANUFACTURING REVENUE, BYFORMULATION, FOR EUROPE, THROUGH 2016 ($ MILLIONS)FIGURE 58 SEMISOLID DOSAGE FORM CONTRACT MANUFACTURING REVENUE, BYFORMULATIONS, FOR EUROPE, 2009-2016 ($ MILLIONS)TABLE 83 SEMISOLID DOSAGE FORM CONTRACT MANUFACTURING MARKETSHARE, BY FORMULATION, FOR EUROPE, 2010 (%)FIGURE 59 SEMISOLID DOSAGE FORM CONTRACT MANUFACTURING MARKETSHARE, BY FORMULATIONS, FOR EUROPE, 2010 (%)CONTRACT MANUFACTURE OF ADVANCED DRUG DELIVERY PRODUCTSMarket OverviewTABLE 84 CONTRACTING COMPANIES PROVIDING DRUG DELIVERY SYSTEMSMarket RevenueTABLE 85 ADVANCED DRUG DELIVERY SYSTEMS REVENUE, BY CONTRACTMANUFACTURING, FOR EUROPE, THROUGH 2016 ($ BILLIONS)FIGURE 60 ADVANCED DRUG DELIVERY SYSTEMS REVENUE, BY CONTRACTMANUFACTURING, FOR EUROPE, 2009-2016 ($ BILLIONS)Market by FormulationTABLE 86 ADVANCED DRUG DELIVERY SYSTEMS BY CONTRACT MANUFACTURINGREVENUE, BY FORMULATION, FOR EUROPE, THROUGH 2016 ($ MILLIONS)FIGURE 61 ADVANCED DRUG DELIVERY SYSTEMS BY CONTRACT MANUFACTURINGREVENUE, BY FORMULATIONS, FOR EUROPE, 2009-2016 ($ MILLIONS)Market ShareTABLE 87 ADVANCED DRUG DELIVERY SYSTEMS BY CONTRACT MANUFACTURINGMARKET SHARE, BY FORMULATION, FOR EUROPE, 2010 (%)FIGURE 62 ADVANCED DRUG DELIVERY SYSTEMS BY CONTRACT MANUFACTURINGMARKET SHARE, BY FORMULATIONS, FOR EUROPE, 2010 (%)CONTRACT MANUFACTURE OF OTC AND NUTRITIONAL PRODUCTSMarket RevenueTABLE 88 OTC AND NUTRITIONAL PRODUCTS REVENUE, BY CONTRACTMANUFACTURING, FOR EUROPE, THROUGH 2016 ($ BILLIONS)FIGURE 63 OTC AND NUTRITIONAL PRODUCTS REVENUE, BY CONTRACTMANUFACTURING, FOR EUROPE, 2009-2016 ($ BILLIONS)Market by FormulationTABLE 89 OTC AND NUTRITIONAL PRODUCTS BY CONTRACT MANUFACTURINGREVENUE, BY FORMULATION, FOR EUROPE, THROUGH 2016 ($ BILLIONS)FIGURE 64 OTC AND NUTRITIONAL PRODUCTS BY CONTRACT MANUFACTURINGREVENUE, BY FORMULATIONS, FOR EUROPE, 2009-2016 ($ BILLIONS)Market SharesTABLE 90 OTC AND NUTRITIONAL PRODUCTS BY CONTRACT MANUFACTURINGMARKET SHARE, BY FORMULATION, FOR EUROPE, 2010 (%)FIGURE 65 OTC AND NUTRITIONAL PRODUCTS BY CONTRACT MANUFACTURINGMARKET SHARE, BY FORMULATIONS, FOR EUROPE, 2010 (%)CONTRACT RESEARCHMARKET OVERVIEWPartnershipsExpansions of FacilitiesMarket Revenue
  14. 14. TABLE 91 CONTRACT RESEARCH REVENUE, FOR EUROPE, THROUGH 2016 ($BILLIONS)FIGURE 66 CONTRACT RESEARCH REVENUE, FOR EUROPE, 2009-2016 ($BILLIONS)Market by DisciplineTABLE 92 CONTRACT RESEARCH REVENUE BY DISCIPLINE, FOR EUROPE,THROUGH 2016 ($ MILLIONS)FIGURE 67 CONTRACT RESEARCH REVENUE BY DISCIPLINE, FOR EUROPE, 2009-2016 ($ MILLIONS)Market Share by DisciplineTABLE 93 CONTRACT RESEARCH MARKET SHARE, BY DISCIPLINE, FOR EUROPE,2010 (%)FIGURE 68 CONTRACT RESEARCH MARKET SHARE, BY DISCIPLINE, FOR EUROPE,2010 (%)CONTRACT PACKAGINGMARKET OVERVIEWMarket RevenueTABLE 94 CONTRACT PACKAGING REVENUE, FOR EUROPE, THROUGH 2016 ($BILLIONS)FIGURE 69 CONTRACT PACKAGING REVENUE, FOR EUROPE, 2009-2016 ($BILLIONS)Market by Package TypeTABLE 95 CONTRACT PACKAGING REVENUE BY TYPE, FOR EUROPE, THROUGH2016 ($ MILLIONS)FIGURE 70 CONTRACT RESEARCH REVENUE BY DISCIPLINE, FOR EUROPE, 2009-2016 ($ BILLIONS)Market Share by TypeTABLE 96 CONTRACT PACKAGING MARKET SHARE BY TYPE, FOR EUROPE, 2010(%)FIGURE 71 CONTRACT PACKAGING MARKET SHARE BY TYPE, FOR EUROPE, 2010(%)CHAPTER SIXTEEN: MARKET ANALYSIS FOR REST OF WORLD/EMERGINGMARKETSCONTRACT MANUFACTURINGCONTRACT MANUFACTURE OF BULK DRUGS/API’SMarket OverviewMarket RevenueTABLE 97 REST OF WORLD BULK DRUG/API’S CONTRACT MANUFACTURINGREVENUE, THROUGH 2016 ($ BILLIONS)FIGURE 72 REST OF WORLD BULK DRUG/API’S CONTRACT MANUFACTURINGREVENUE, 2009-2016 ($ BILLIONS)CONTRACT MANUFACTURE OF ORAL DOSAGEFORMULATIONSSolid Dosage FormulationsMarket OverviewMarket Revenue
  15. 15. TABLE 98 SOLID DOSAGE FORM CONTRACT MANUFACTURING, FOR REST OFWORLD, THROUGH 2016 ($ BILLIONS)FIGURE 73 SOLID DOSAGE FORM CONTRACT MANUFACTURING, FOR REST OFWORLD, 2009-2016 ($ BILLIONS)Market by FormulationMarket RevenueTABLE 99 SOLID DOSAGE FORM CONTRACT MANUFACTURING REVENUE, BYFORMULATION, FOR REST OF WORLD, THROUGH 2016 ($ BILLIONS)FIGURE 74 SOLID DOSAGE FORM CONTRACT MANUFACTURING REVENUE, BYFORMULATION, FOR REST OF WORLD, 2009-2016 ($ BILLIONS)TABLE 100 SOLID DOSAGE FORM CONTRACT MANUFACTURING MARKET SHARE, BYFORMULATION, FOR REST OF WORLD, 2010 (%)FIGURE 75 SOLID DOSAGE FORM CONTRACT MANUFACTURING MARKET SHARE BYFORMULATION, FOR REST OF WORLD, 2010 (%)Liquid Dosage FormulationMarket OverviewMarket RevenueNonsterile FormulationsTABLE 101 LIQUID DOSAGE FORM (NONSTERILE) CONTRACT MANUFACTURINGFOR REST OF WORLD, THROUGH 2016 ($ MILLIONS)FIGURE 76 LIQUID DOSAGE FORM (NONSTERILE) CONTRACT MANUFACTURINGFOR REST OF WORLD, 2009-2016 ($ MILLIONS)Sterile FormulationsTABLE 102 LIQUID DOSAGE FORM (STERILE) CONTRACT MANUFACTURING, FORREST OF WORLD, THROUGH 2016 ($ MILLIONS)FIGURE 77 LIQUID DOSAGE FORM (STERILE) CONTRACT MANUFACTURING, FORREST OF WORLD, 2009-2016 ($ MILLIONS)Market by FormulationNonsterile FormulationsTABLE 103 LIQUID DOSAGE FORM (NONSTERILE) CONTRACT MANUFACTURINGREVENUE, BY FORMULATION, FOR REST OF WORLD, THROUGH 2016 ($ MILLIONS)FIGURE 78 LIQUID DOSAGE FORM (NONSTERILE) CONTRACT MANUFACTURINGREVENUE, BY FORMULATION, FOR REST OF WORLD, 2009-2016 ($ MILLIONS)TABLE 104 LIQUID DOSAGE FORM (NONSTERILE) CONTRACT MANUFACTURINGMARKET SHARE, BY FORMULATION, FOR REST OF WORLD, 2010 (%)FIGURE 79 LIQUID DOSAGE FORM (NONSTERILE) CONTRACT MANUFACTURINGMARKET SHARE, BY FORMULATION, FOR REST OF WORLD, 2010 (%)Sterile FormulationsTABLE 105 LIQUID DOSAGE FORM (STERILE) CONTRACT MANUFACTURINGREVENUE BY FORMULATION FOR REST OF WORLD, THROUGH 2016 ($ MILLIONS)FIGURE 80 LIQUID DOSAGE FORM (STERILE) CONTRACT MANUFACTURINGREVENUE BY FORMULATION, FOR REST OF WORLD, 2009-2016 ($ MILLIONS)TABLE 106 LIQUID DOSAGE FORM (STERILE) CONTRACT MANUFACTURINGMARKET SHARE, BY FORMULATION, FOR REST OF WORLD, 2010 (%)FIGURE 81 LIQUID DOSAGE FORM (STERILE) CONTRACT MANUFACTURINGMARKET SHARE, BY FORMULATION, FOR REST OF WORLD, 2010 (%)CONTRACT MANUFACTURE OF SEMISOLID DOSAGE FORMULATIONS
  16. 16. Market OverviewMarket RevenueTABLE 107 SEMISOLID DOSAGE FORM CONTRACT MANUFACTURING, FOR REST OFWORLD, THROUGH 2016 ($ MILLIONS)FIGURE 82 SEMISOLID DOSAGE FORM CONTRACT MANUFACTURING, FOR REST OFWORLD, 2009-2016 ($ MILLIONS)Market by FormulationTABLE 108 SEMISOLID DOSAGE FORM CONTRACT MANUFACTURING REVENUE BYFORMULATION, FOR REST OF WORLD, THROUGH 2016 ($ MILLIONS)FIGURE 83 SEMISOLID DOSAGE FORM CONTRACT MANUFACTURING REVENUE BYFORMULATION, FOR REST OF WORLD, 2009-2016 ($ MILLIONS)TABLE 109 SEMISOLID DOSAGE FORM CONTRACT MANUFACTURING MARKETSHARE BY FORMULATION, FOR REST OF WORLD, 2010 (%)FIGURE 84 SEMISOLID DOSAGE FORM CONTRACT MANUFACTURING MARKETSHARE BY FORMULATION, FOR REST OF WORLD, 2010 (%)CONTRACT MANUFACTURE OF ADVANCED DRUG DELIVERY PRODUCTSMarket OverviewTABLE 110 CONTRACTING COMPANIES PROVIDING DRUG DELIVERY SYSTEMS INROWTABLE 111 ADVANCED DRUG DELIVERY SYSTEMS REVENUE BY CONTRACTMANUFACTURING, FOR REST OF WORLD, THROUGH 2016 ($ BILLIONS)FIGURE 85 ADVANCED DRUG DELIVERY SYSTEMS REVENUE BY CONTRACTMANUFACTURING, FOR REST OF WORLD, THROUGH 2016 ($ BILLIONS)Market by FormulationTABLE 112 ADVANCED DRUG DELIVERY SYSTEMS BY CONTRACT MANUFACTURINGREVENUE, BY FORMULATION, FOR REST OF WORLD, THROUGH 2016 ($ MILLIONS)FIGURE 86 ADVANCED DRUG DELIVERY SYSTEMS BY CONTRACT MANUFACTURINGREVENUE, BY FORMULATION, FOR REST OF WORLD, 2009-2016 ($ MILLIONS)Market ShareTABLE 113 ADVANCED DRUG DELIVERY SYSTEMS BY CONTRACT MANUFACTURINGMARKET SHARE, BY FORMULATION, FOR REST OF WORLD, 2010 (%)FIGURE 87 ADVANCED DRUG DELIVERY SYSTEMS BY CONTRACT MANUFACTURINGMARKET SHARE, BY FORMULATION, FOR REST OF WORLD, 2010 (%)CONTRACT MANUFACTURE OF OTC AND NUTRITIONAL PRODUCTSMarket RevenueTABLE 114 OTC AND NUTRITIONAL PRODUCTS REVENUE BY CONTRACTMANUFACTURING, FOR REST OF WORLD, THROUGH 2016 ($ BILLIONS)FIGURE 88 OTC AND NUTRITIONAL PRODUCTS REVENUE BY CONTRACTMANUFACTURING, FOR REST OF WORLD, 2009-2016 ($ BILLIONS)TABLE 115 OTC AND NUTRITIONAL PRODUCTS BY CONTRACT MANUFACTURINGREVENUE, BY FORMULATION, FOR REST OF WORLD, THROUGH 2016 ($ BILLIONS)FIGURE 89 OTC AND NUTRITIONAL PRODUCTS BY CONTRACT MANUFACTURINGREVENUE, BY FORMULATIONS, FOR REST OF WORLD, 2009-2016 ($ BILLIONS)Market SharesTABLE 116 OTC AND NUTRITIONAL PRODUCTS BY CONTRACT MANUFACTURINGMARKET SHARE, BY FORMULATION, FOR REST OF WORLD, 2010 (%)FIGURE 90 OTC AND NUTRITIONAL PRODUCTS BY CONTRACT MANUFACTURING
  17. 17. MARKET SHARE, BY FORMULATION, FOR REST OF WORLD, 2009-2016 (%)CONTRACT RESEARCHMARKET OVERVIEWPartnershipsExpansions of FacilitiesMarket RevenueTABLE 117 CONTRACT RESEARCH REVENUE FOR REST OF WORLD, THROUGH 2016($ BILLIONS)FIGURE 91 CONTRACT RESEARCH REVENUE FOR REST OF WORLD, 2009-2016 ($BILLIONS)Market by DisciplineTABLE 118 CONTRACT RESEARCH REVENUE BY DISCIPLINE, FOR REST OF WORLD,THROUGH 2016 ($ BILLIONS)FIGURE 92 CONTRACT RESEARCH REVENUE BY DISCIPLINE, FOR REST OF WORLD,2009-2016 ($ BILLIONS)Market Shares by DisciplineTABLE 119 CONTRACT RESEARCH MARKET SHARE BY DISCIPLINE, FOR REST OFWORLD, 2010 (%)FIGURE 93 CONTRACT RESEARCH MARKET SHARE BY DISCIPLINE, FOR REST OFWORLD, 2010 (%)CONTRACT PACKAGINGMARKET OVERVIEWTABLE 120 CONTRACT PACKAGING REVENUE, FOR REST OF WORLD, THROUGH2016 ($ BILLIONS)FIGURE 94 CONTRACT PACKAGING REVENUE, FOR REST OF WORLD, 2009-2016 ($BILLIONS)Market by Package TypeMarket RevenueTABLE 121 CONTRACT PACKAGING REVENUE BY TYPE, FOR REST OF WORLD,THROUGH 2016 ($ MILLIONS)FIGURE 95 CONTRACT RESEARCH REVENUE BY DISCIPLINE FOR REST OF WORLD,THROUGH 2016 ($ MILLIONS)Market Share by TypeTABLE 122 CONTRACT PACKAGING MARKET SHARE BY TYPE, FOR REST OF WORLD,2010 (%)FIGURE 96 CONTRACT PACKAGING MARKET SHARE BY TYPE, FOR REST OF WORLD,2010 (%)CHAPTER SEVENTEEN: MARKET SHARE BY REGIONMARKET SHARE OF CONTRACT MANUFACTURED API’STABLE 123 BULK DRUG/API CONTRACT MANUFACTURING MARKET SHARE, BYREGION, 2010 (%)FIGURE 97 BULK DRUG/API CONTRACT MANUFACTURING MARKET SHARE, BYREGION, 2010 (%)MARKET SHARE OF CONTRACT MANUFACTURED SOLID DOSAGE FORMSTABLE 124 SOLID DOSAGE FORM CONTRACT MANUFACTURING MARKET SHARE, BYREGION, 2010 (%)
  18. 18. FIGURE 98 SOLID DOSAGE FORM CONTRACT MANUFACTURING MARKET SHARE, BYREGION, 2010 (%)MARKET SHARE OF CONTRACT MANUFACTURED LIQUID DOSAGE FORMULATIONSNONSTERILE FORMULATIONSTABLE 125 LIQUID DOSAGE FORM (NONSTERILE) CONTRACT MANUFACTURINGMARKET SHARE, BY REGION, 2010 (%)FIGURE 99 LIQUID DOSAGE FORM (NONSTERILE) CONTRACT MANUFACTURINGMARKET SHARE, BY REGION, 2010 (%)STERILE FORMULATIONSTABLE 126 LIQUID DOSAGE FORM (STERILE) CONTRACT MANUFACTURINGMARKET SHARE, BY REGION, 2010 (%)FIGURE 100 LIQUID DOSAGE FORM (STERILE) CONTRACT MANUFACTURINGMARKET SHARE, BY REGION, 2010 (%)MARKET SHARE OF CONTRACT MANUFACTURED SEMISOLIDDOSAGE FORMULATIONSTABLE 127 SEMISOLID DOSAGE FORM CONTRACT MANUFACTURING MARKETSHARES, BY REGION, 2010 (%)FIGURE 101 SEMISOLID DOSAGE FORM CONTRACT MANUFACTURING MARKETSHARE, BY REGION, 2010 (%)MARKET SHARE OF CONTRACT MANUFACTURED ADVANCED DRUG DELIVERYPRODUCTSTABLE 128 DRUG DELIVERY CONTRACT MANUFACTURING MARKET SHARE, BYREGION, 2010 (%)FIGURE 102 DRUG DELIVERY CONTRACT MANUFACTURING MARKET SHARE, BYREGION, 2010 (%)MARKET SHARE OF CONTRACT MANUFACTURED OTC AND NUTRITIONALPRODUCTSTABLE 129 OTC AND NUTRITIONAL PRODUCTS CONTRACT MANUFACTURINGMARKET SHARE, BY REGION, 2010 (%)FIGURE 103 OTC AND NUTRITIONAL PRODUCT CONTRACT MANUFACTURINGMARKET SHARE, BY REGION, 2010 (%)MARKET SHARE OF CONTRACT RESEARCHTABLE 130 CONTRACT RESEARCH MARKET SHARE, BY REGION, 2010 (%)FIGURE 104 CONTRACT RESEARCH MARKET SHARE, BY REGION, 2010 (%)MARKET SHARE OF CONTRACT PACKAGINGTABLE 131 CONTRACT PACKAGING MARKET SHARE, BY REGION, 2010 (%)FIGURE 105 CONTRACT PACKAGING MARKET SHARE, BY REGION, 2010 (%)CHAPTER EIGHTEEN: CONTRACT MANUFACTURING APPLICATIONS FORNORTH AMERICAN MARKETSCARDIOVASCULAR DRUGSMARKET REVENUETABLE 132 REVENUE FROM CONTRACT MANUFACTURERS OF CARDIOVASCULARDRUGS, IN NORTH AMERICA, THROUGH 2016 ($ MILLIONS)FIGURE 106 REVENUE FROM CONTRACT MANUFACTURERS OF CARDIOVASCULARDRUGS, IN NORTH AMERICA, 2009-2016 ($ MILLIONS)REPRODUCTIVE DRUG MARKET
  19. 19. MARKET REVENUETABLE 133 REVENUE FROM CONTRACT MANUFACTURERS OF REPRODUCTIVEDRUGS, IN NORTH AMERICA, THROUGH 2016 ($ MILLIONS)FIGURE 107 REVENUE FROM CONTRACT MANUFACTURERS OF REPRODUCTIVEDRUGS, IN NORTH AMERICA, 2009-2016 ($ MILLIONS)ONCOLOGY DRUG MARKETMARKET REVENUETABLE 134 REVENUE FROM CONTRACT MANUFACTURERS OF ONCOLOGY DRUGS,IN NORTH AMERICA, THROUGH 2016 ($ MILLIONS)FIGURE 108 REVENUE FROM CONTRACT MANUFACTURERS OF ONCOLOGY DRUGS,IN NORTH AMERICA, 2009-2016 ($ MILLIONS)ANALGESICS MARKETMARKET REVENUETABLE 135 REVENUE FROM CONTRACT MANUFACTURERS OF ANALGESICS, INNORTH AMERICA, THROUGH 2016 ($ MILLIONS)FIGURE 109 REVENUE FROM CONTRACT MANUFACTURERS OF ANALGESICS, INNORTH AMERICA, 2009-2016 ($ MILLIONS)MARKET REVENUETABLE 136 REVENUE FROM CONTRACT MANUFACTURERS OF ANTIVIRALS, INNORTH AMERICA, THROUGH 2016 ($ MILLIONS)FIGURE 110 REVENUE FROM CONTRACT MANUFACTURERS OF ANTIVIRALS, INNORTH AMERICA, 2009-2016 ($ MILLIONS)ANTIBIOTICS MARKETMARKET REVENUETABLE 137 REVENUE FROM CONTRACT MANUFACTURERS OF ANTIBIOTICS, INNORTH AMERICA, THROUGH 2016 ($ MILLIONS)FIGURE 111 REVENUE FROM CONTRACT MANUFACTURERS OF ANTIBIOTICS, INNORTH AMERICA, 2009-2016 ($ MILLIONS)MARKETS FOR OTHER DRUGSMARKET REVENUETABLE 138 REVENUE FROM CONTRACT MANUFACTURERS OF OTHER DRUGS, INNORTH AMERICA, THROUGH 2016 ($ BILLIONS)FIGURE 112 REVENUE FROM CONTRACT MANUFACTURERS OF OTHER DRUGS, INNORTH AMERICA, 2009-2016 ($ BILLIONS)CHAPTER NINETEEN: CONTRACT MANUFACTURING APPLICATIONS FOREUROPEAN MARKETSCARDIOVASCULAR DRUGSMARKET REVENUETABLE 139 REVENUE FROM CONTRACT MANUFACTURERS OF CARDIOVASCULARDRUGS, IN EUROPE, THROUGH 2016 ($MILLIONS)FIGURE 113 REVENUE FROM CONTRACT MANUFACTURERS OF CARDIOVASCULARDRUGS, IN EUROPE, 2009-2016 ($ MILLIONS)REPRODUCTIVE DRUG MARKETMARKET REVENUETABLE 140 REVENUE FROM CONTRACT MANUFACTURERS OF REPRODUCTIVEDRUGS, IN EUROPE, THROUGH 2016 ($ MILLIONS)
  20. 20. FIGURE 114 REVENUE FROM CONTRACT MANUFACTURERS OF REPRODUCTIVEDRUGS, IN EUROPE, 2009-2016 ($ MILLIONS)ONCOLOGY DRUG MARKETMARKET REVENUETABLE 141 REVENUE FROM CONTRACT MANUFACTURERS OF ONCOLOGY DRUGS,IN EUROPE, THROUGH 2016 ($ MILLIONS)FIGURE 115 REVENUE FROM CONTRACT MANUFACTURERS OF ONCOLOGY DRUGS,IN EUROPE, 2009-2016 ($ MILLIONS)ANALGESICS MARKETMARKET REVENUETABLE 142 REVENUE FROM CONTRACT MANUFACTURERS OF ANALGESICS, INEUROPE, THROUGH 2016 ($ MILLIONS)FIGURE 116 REVENUE FROM CONTRACT MANUFACTURERS OF ANALGESICS, INEUROPE, 2009-2016 ($ MILLIONS)ANTIVIRAL DRUG MARKETMARKET REVENUETABLE 143 REVENUE FROM CONTRACT MANUFACTURERS OF ANTIVIRALS, INEUROPE, THROUGH 2016 ($ MILLIONS)FIGURE 117 REVENUE FROM CONTRACT MANUFACTURERS OF ANTIVIRALS, INEUROPE, 2009-2016 ($ MILLIONS)ANTIBIOTICS MARKETMARKET REVENUETABLE 144 REVENUE FROM CONTRACT MANUFACTURERS OF ANTIBIOTICS, INEUROPE, THROUGH 2016 ($ MILLIONS)FIGURE 118 REVENUE FROM CONTRACT MANUFACTURERS OF ANTIBIOTICS, INEUROPE, 2009-2016 ($ MILLIONS)MARKETS FOR OTHER DRUGSMARKET REVENUETABLE 145 REVENUE FROM CONTRACT MANUFACTURERS OF OTHER DRUGS, INEUROPE, THROUGH 2016 ($ BILLIONS)FIGURE 119 REVENUE FROM CONTRACT MANUFACTURERS OF OTHER DRUGS, INEUROPE, 2009-2016 ($ BILLIONS)CHAPTER TWENTY: CONTRACT MANUFACTURING APPLICATIONS FOR RESTOF THE WORLD (ROW)CARDIOVASCULAR DRUGSMARKET REVENUETABLE 146 REVENUE FROM CONTRACT MANUFACTURERS OF CARDIOVASCULARDRUGS, IN REST OF WORLD, THROUGH 2016 ($ MILLIONS)FIGURE 120 REVENUE FROM CONTRACT MANUFACTURERS OF CARDIOVASCULARDRUGS, IN REST OF WORLD, 2009-2016 ($ MILLIONS)REPRODUCTIVE DRUG MARKETMARKET REVENUETABLE 147 REVENUE FROM CONTRACT MANUFACTURERS OF REPRODUCTIVEDRUGS, IN REST OF WORLD, THROUGH 2016 ($ MILLIONS)FIGURE 121 REVENUE FROM CONTRACT MANUFACTURERS OF REPRODUCTIVEDRUGS, IN REST OF WORLD, 2009-2016 ($ MILLIONS)
  21. 21. ONCOLOGY DRUG MARKETMARKET REVENUETABLE 148 REVENUE FROM CONTRACT MANUFACTURERS OF DRUGS USED INONCOLOGY, IN REST OF WORLD, THROUGH 2016 ($ MILLIONS)FIGURE 122 REVENUE FROM CONTRACT MANUFACTURERS OF DRUGS USED INONCOLOGY, IN REST OF WORLD, 2009-2016 ($ MILLIONS)ANALGESICS MARKETMARKET REVENUETABLE 149 REVENUE FROM CONTRACT MANUFACTURERS OF ANALGESICS, INREST OF WORLD, THROUGH 2016 ($ MILLIONS)FIGURE 123 REVENUE FROM CONTRACT MANUFACTURERS OF ANALGESICS, INREST OF WORLD, 2009-2016 ($ MILLIONS)ANTIVIRAL DRUG MARKETMARKET REVENUETABLE 150 REVENUE FROM CONTRACT MANUFACTURERS OF ANTIVIRALS, IN RESTOF WORLD, THROUGH 2016 ($ MILLIONS)FIGURE 124 REVENUE FROM CONTRACT MANUFACTURERS OF ANTIVIRALS, INREST OF WORLD, 2009-2016 ($ MILLIONS)ANTIBIOTICS MARKETMARKET REVENUETABLE 151 REVENUE FROM CONTRACT MANUFACTURERS OF ANTIBIOTICS, INREST OF WORLD, THROUGH 2016 ($ MILLIONS)FIGURE 125 REVENUE FROM CONTRACT MANUFACTURERS OF ANTIBIOTICS, INREST OF WORLD, 2009-2016 ($ MILLIONS)MARKETS FOR OTHER DRUGSMARKET REVENUETABLE 152 REVENUE FROM CONTRACT MANUFACTURERS OF OTHER DRUGS, INREST OF WORLD, THROUGH 2016 ($ BILLIONS)FIGURE 126 REVENUE FROM CONTRACT MANUFACTURERS OF OTHER DRUGS, INREST OF WORLD, 2009-2016 ($ BILLIONS)CHAPTER TWENTY-ONE: PATENT ANALYSISPATENTS BY YEARTABLE 153 NUMBER OF SIGNIFICANT PATENTS, BY YEAR, 2009-2011FIGURE 127 NUMBER OF PATENTS, BY YEAR, 2009-MAY 31, 2011FIGURE 128 NUMBER OF PATENTS, BY YEAR, 2009-MAY 31, 2011 (%)PATENTS BY COMPANYTABLE 154 NUMBER OF U.S. PATENTS, BY COMPANY, 2009-2011FIGURE 129 NUMBER OF U.S. PATENTS, BY COMPANY, 2009-2011PATENTS BY COUNTRYTABLE 155 NUMBER OF U.S. PATENTS, BY COUNTRY, 1/1/2009 TO 5/31/2011FIGURE 130 NUMBER OF U.S. PATENTS, BY COUNTRY, 1/1/2009 TO 5/31/2011TABLE 156 PATENT SHARES, BY COUNTRY, 1/1/2009 TO 5/31/2011 (%)FIGURE 131 PATENT SHARES, BY COUNTRY, 1/1/2009 TO 5/31/2011 (%)PATENTS BY EMPHASIS TABLE 157 PATENTS, BY EMPHASIS, 1/1/2009 TO 5/31/2011FIGURE 132 NUMBER OF U.S. PATENTS, BY EMPHASIS, 1/1/2009 TO 5/31/2011
  22. 22. CHAPTER TWENTY-TWO: CURRENT ENVIRONMENTSITUATION OF THE NORTH AMERICAN CONTRACTING MARKETSCONTRACT MANUFACTURING OF API AND DOSAGE FORMSCONTRACT MANUFACTURING OF OTC AND NUTRACEUTICALSCONTRACT RESEARCHCONTRACT PACKAGINGSITUATION OF THE EUROPEAN CONTRACTING MARKETCONTRACT MANUFACTURING OF API AND DOSAGE FORMSCONTRACT MANUFACTURING OF OTC AND NUTRACEUTICALSCONTRACT RESEARCHCONTRACT PACKAGINGSITUATION OF THE ROW CONTRACTING MARKETCONTRACT MANUFACTURING OF API AND DOSAGE FORMSCONTRACT MANUFACTURING OF OTC AND NUTRACEUTICALSCONTRACT RESEARCHCONTRACT PACKAGINGOPPORTUNITIES AND CHALLENGES OF THE CURRENT CONTRACT MANUFACTURINGINDUSTRYCHAPTER TWENTY-THREE: COMPANY PROFILESAAI PHARMA, INC.ABBOTT LABORATORIESAEROGEN LTD.ALKERMESALTHEA TECHNOLOGIESAMCORAMERISOURCE BERGEN CORPORATIONAMPAC FINE CHEMICALSALBANY MOLECULAR RESEARCH INC. (AMRI)AP PHARMA INC.APTUIT INC.ARADIGM CORPORATIONBASF SEBAXTER HEALTHCAREBCM/BOOTS MANUFACTURINGBOEHRINGER INGELHEIMBRISTOL-MYERS SQUIBBCAMBREX CORPORATIONCANGENE CORPORATIONCATALENT PHARMA SOLUTIONSCEDARBURG HAUSER PHARMACEUTICALS INC.CENEXICHARLES RIVER LABORATORIESCHEMBRIDGE CORP.CLEARSTONE CENTRAL LABORATORIESCONFAB LABORATORIES
  23. 23. COVANCE INC.COVIDIENCONTRACT PHARMACEUTICALS LIMITEDCORDEN PHARMA SWITZERLAND LLCDAVOS PHARMADECODE GENETICSDISHMAN PHARMACEUTICALS AND CHEMICALS LTD.DOW CHEMICALDPT LABORATORIES INC.DR. REDDY’S LABORATORIESDSM PHARMACEUTICAL PRODUCTSFUJIFILM DIOSYNTH BIOTECHNOLOGYELAN DRUG TECHNOLOGIESEVOTEC AGFULCRUM PHARMA PLCGIRINDUS AGGLAXOSMITHKLINEHOSPIRAHAUPT PHARMA AGHOVIONE S.AICON PLCINC RESEARCH, INC.JUBILANT LIFESCIENCESKENDLE INTERNATIONAL INC.KP PHARMACEUTICAL TECHNOLOGIES INC.K.V. PHARMACEUTICAL CO.LIGAND PHARMACEUTICALS, INC.LONZA GROUPLYNE LABORATORIESMERCK / MSD BIOMANUFACTURING NETWORKMIKART INCNEXTPHARMA TECHNOLOGIESNORWICH PHARMACEUTICALSNOVAVAX, INC.OMNICARE CLINICAL RESEARCHPAREXEL INTERNATIONAL CORPORATIONPATHEON INC.PERRIGO COMPANYPFIZER (KING PHARMACEUTICALS)PIRAMAL HEALTHCARE LIMITEDPPDPRA INTERNATIONALQUINTILESRANBAXYREGIS TECHNOLOGIES, INC.SKYEPHARMATALECRIS BIOTHERAPEUTICS INC.
  24. 24. VETTER PHARMA INTERNATIONAL GMBHWOCKHARDT LIMITEDWUXI APP TECXCELLEREX LLCZACH SYSTEM S.P.AAPPENDIX I: ABBREVIATIONSAbout Us:ReportsnReports is an online library of over 100,000+ market research reports andin-depth market research studies & analysis of over 5000 micro markets. Weprovide 24/7 online and offline support to our customers. Get in touch with us foryour needs of market research reports.Follow us on Twitter: http://twitter.com/marketsreportsOur Facebook Page:http://www.facebook.com/pages/ReportsnReports/191441427571689Contact:Mr.Priyank7557 Rambler road,Suite727,Dallas,TX75231Tel: + 1 888 391 5441E-mail: sales@reportsandreports.comhttp://www.reportsnreports.comVisit our Market Research Blog

×